OXGN Has been trading on low volume for the last 4 1/2 months and has been holding above the 4,30 level
The stock needs to close above 4.90 before it could test its June 21 H at 5.22 but the insiders have been buying some this month at $4.58 & $4.68 <g>
bigcharts.marketwatch.com
The longer term chart remains "interesting".<g>
bigcharts.marketwatch.com
OXGN reportedly has around $1.90 in cash/shr and no significant LTD
On June 20 it gave an update on its VTAs for MMD & wAMD on which they are having PIIs & planning PIIs
And on May 16,it announced that its CA4P was well tolerated when combined with radiotherapy in the PIb in patients with advanced Ca. (With advanced NSCLC, or with prostatic Ca )
"Evidence of blood flow shutdown was seen in many of the tumors evaluated suggesting that the dose of CA4P was biologically active and potentially synergistic with radiotherapy." according to he lead investigator of the study, Professor Peter Hoskin, from the Mount Vernon Cancer Centre in the United Kingdom.
"Although it is too early to evaluate any prolonged response in the prostate patients we are very encouraged by the results seen in the NSCLC patients both in terms of the low toxicity, tumor response and patient survival and based on this positive early data we anticipate moving forward with an international, multi-center trial in late 2005."
CA4P is being studied in seven trials in oncology, including anaplastic thyroid, lung, head and neck, prostate, colorectal, ovarian, cervical cancers and other tumor types as a single agent and in combination therapies.
Bernard |
